AAPS announces speakers and sessions for PharmSci 360
The American Association of Pharmaceutical Scientists (AAPS) has announced details of its 2026 PharmSci 360 conference, including opening and closing plenary speakers, a collaboration with the United States Pharmacopeia (USP) and two Innovator-Curated tracks.
The event will take place from October 25–28 at the Ernest N Morial Convention Center in New Orleans, Louisiana, bringing together pharmaceutical scientists to discuss research, technologies and techniques across the pharmaceutical continuum.
Plenary speakers
Julie Gerberding, President and CEO of the Foundation for the National Institutes of Health (FNIH), will open the conference on October 25. She previously directed the US Centers for Disease Control and Prevention from 2002–2009 and has held executive roles at Merck.
David Berry, Managing Partner at Averin Capital, will conclude the event on October 28. He co-founded Averin to drive improvements in health outcomes through emerging technologies and has previously co-founded more than 30 life sciences and sustainability companies.
USP-hosted sessions
AAPS and USP will collaborate on a two-and-a-half-day workshop from October 26–28, expanding educational opportunities through sessions providing access to insights on compendial standards presented by USP scientists and expert volunteers.
The workshop will cover scientific and regulatory topics including complex generics, excipient quality, inhalation standards, emerging standards and novel excipients. Discussions will address scientific challenges, evolving standards and opportunities to support innovation and quality across the pharmaceutical lifecycle.
New tracks explore research and technology
The conference will introduce two Innovator-Curated tracks addressing scientific research integrity and disruptive technologies in drug development.
On October 26, Brian Nosek, Co-founder and Executive Director of the Center for Open Science, will lead six sessions focused on credibility in peer-reviewed research. Topics include identifying problematic papers, ensuring citations are credible and implementing ethical practices for using AI in research.
On October 28, Thomas Hartung, Professor at the Johns Hopkins University Bloomberg School of Public Health, will lead sessions exploring new approaches to testing models, including AI applications, organ-on-a-chip models and neural organoids.
“I am excited to see the launch of the Innovator-Curated tracks at PharmSci 360. This initiative creates a unique opportunity to introduce emerging areas of pharmaceutical science, showcase visionary leaders, and spark new ideas that will shape the future of our field,” AAPS Scientific Advisory Committee Chair Dan Bow, said. “We believe these tracks will inspire collaboration, broaden perspectives, and help drive the next generation of scientific innovation.”
Registration for PharmSci 360 is open via the AAPS website: www.science360.aaps.org
